PDS Biotechnology
PDSB
46 hedge funds and large institutions have $109M invested in PDS Biotechnology in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
18% more funds holding
Funds holding: 39 → 46 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
31% less capital invested
Capital invested by funds: $158M → $109M (-$48.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.02M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.65M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$883K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$618K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$231K |
| 3 |
D.E. Shaw & Co
New York
|
-$197K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$106K |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$63.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| – | -$3K | -10 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$1K | -6 | Closed |
|
PDSB Hedge Fund Activity: Q1 2016 in Review
46 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2016, worth a combined $109M — down 31% from $158M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PDSB positions and 6 closed out — a net gain of 7 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was Acuta Capital Partners, adding an estimated $2.02M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.
- 46 institutional investors held PDS Biotechnology (PDSB) as of Q1 2016, up from 39 in Q4 2015.
- Funds reported $109M of PDS Biotechnology stock for Q1 2016, down 31% quarter-over-quarter.
- 13 funds opened new PDS Biotechnology positions in Q1 2016 and 6 closed out, a net change of +7 holders.
- The largest PDS Biotechnology buyer in Q1 2016 was Acuta Capital Partners, an estimated $2.02M added.
- The largest PDS Biotechnology seller in Q1 2016 was Fidelity Investments, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2016.